Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Otomax is a veterinary otic ointment indicated for the treatment of acute and chronic otitis externa in dogs. It is a fixed-dose combination product containing three active ingredients: gentamicin sulfate, betamethasone valerate, and clotrimazole. Gentamicin is an aminoglycoside antibiotic that provides bactericidal activity by binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis. Betamethasone valerate is a synthetic corticosteroid that exerts anti-inflammatory and antipruritic effects by activating the glucocorticoid receptor. Clotrimazole is an imidazole antifungal agent that inhibits the enzyme lanosterol 14-alpha demethylase, leading to the depletion of ergosterol and disruption of fungal cell membrane integrity. Developed by Schering-Plough and now marketed by Merck Animal Health, Otomax is effective against common canine ear pathogens, including *Malassezia pachydermatis*, *Staphylococcus aureus*, and *Pseudomonas aeruginosa*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin + betamethasone + clotrimazole.